Chemical Structure : CRE-14
CAS No.:
2674161-69-2
CRE-14
(CRE14)
Catalog No.: PC-23932Not For Human Use, Lab Use Only.
CRE-14 is a specific, high affinity inhibitor of fatty acid-binding protein 4 (FABP4) with Kd of 654 nM in MST assays, impairs coronavirus replication.
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
CRE-14 is a specific, high affinity inhibitor of fatty acid-binding protein 4 (FABP4) with Kd of 654 nM in MST assays, impairs coronavirus replication.
CRE-14 blocks FABP4's ability to bind its lipid ligand (BODIPY FL C12) in TR-FRET assays.
CRE-14 reduces SARS-CoV-2 virus nucleocapsid protein levels, reduces virus titers and disrupts replication organelles formation in adipocytes.
CRE-14 (5-10 uM) reduces viral titers across various SARS-CoV-2 variants in HBE cells.
CRE-14 (15 mg/kg, s.c.) significantly ameliorated the infection-associated weight loss and reduced lung viral titers in infected hamsters.
Physicochemical Properties
|
M.Wt
|
376.50
|
|
Formula
|
C24H28N2O2
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
N-(6-hexyl-4-phenylquinolin-2-yl)-N-methylglycine
|
References
1. Baazim H, et al. EMBO Mol Med. 2025 Jan 22. doi: 10.1038/s44321-024-00188-x.
2. Koyuncu E, Kim H, Hotamisligil G (2023) Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases - US Patent Application 17/566692, Pub. No.: US20230210837A1
Contact Us
sales@probechem.com
